These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 16289236

  • 21. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion.
    Shyu KG, Hsu FL, Wang MJ, Wang BW, Lin S.
    Exp Cell Res; 2007 Apr 01; 313(6):1181-91. PubMed ID: 17335808
    [Abstract] [Full Text] [Related]

  • 22. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov 01; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

  • 23. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K.
    Cancer; 1996 Aug 01; 78(3):487-92. PubMed ID: 8697395
    [Abstract] [Full Text] [Related]

  • 24. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.
    Clin Cancer Res; 2007 Dec 15; 13(24):7388-93. PubMed ID: 18094421
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
    Kim CM, Vocke C, Torres-Cabala C, Yang Y, Schmidt L, Walther M, Linehan WM.
    J Urol; 2006 May 15; 175(5):1908-14. PubMed ID: 16600797
    [Abstract] [Full Text] [Related]

  • 29. Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
    Takano Y, Iwata H, Yano Y, Miyazawa M, Virgona N, Sato H, Ueno K, Yano T.
    Biochem Pharmacol; 2010 Aug 15; 80(4):463-70. PubMed ID: 20510207
    [Abstract] [Full Text] [Related]

  • 30. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb 15; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 31. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia.
    Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL.
    Cancer Res; 2003 Oct 01; 63(19):6130-4. PubMed ID: 14559790
    [Abstract] [Full Text] [Related]

  • 32. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
    Wagner SN, Atkinson MJ, Thanner S, Wagner C, Schmitt M, Wilhelm O, Rotter M, Höfler H.
    Am J Pathol; 1995 Jul 01; 147(1):183-92. PubMed ID: 7604879
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct 01; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 35. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
    Sandlund J, Ljungberg B, Wikström P, Grankvist K, Lindh G, Rasmuson T.
    Acta Oncol; 2009 Oct 01; 48(6):909-14. PubMed ID: 19322701
    [Abstract] [Full Text] [Related]

  • 36. [Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human renal cell carcinoma].
    Shao ZQ, Zheng SB, Xiao YJ, Tan WL, Chen T, Qi H, Jiang YD, Yu ZC, Zhang HJ.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug 01; 25(8):1034-6. PubMed ID: 16109571
    [Abstract] [Full Text] [Related]

  • 37. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007 Aug 01; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 38. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb 01; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 39. In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue.
    Bruse C, Radu D, Bergqvist A.
    Mol Hum Reprod; 2004 Mar 01; 10(3):159-66. PubMed ID: 14981142
    [Abstract] [Full Text] [Related]

  • 40. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
    Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B.
    Eur Urol; 2006 Dec 01; 50(6):1272-7. PubMed ID: 16814458
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.